CTO is an important candidate for cancer therapy because:
inhibit angiogenesis, inhibit intracellular calcium influx, inhibit signal transduction and ultimately down-regulation of the production of regulatory proteins responsible for tumor invasion and metastases,
inhibit VEGF,
induce apoptosis
inhibit cyclooxygenase
CTO was more effective in inhibiting a variety of experimental tumors including prostate, melanoma, colon, etc.
CTO, given alone, is equally effective in inhibiting colon tumors in mice in comparison with AVASTIN alone.
CTO in combination with 5-FU has greater efficacy than AVASTIN+5-FU in HT29 colon xenograft model.
CTO in combination with Temodar has greater efficacy than Temodar alone in SC251 human glioblastoma xenograft model.
When given in Combination with 5 Fluorouracil, CAI Orotate was maybe more effective in inhibiting the colon tumors compared with AVASTIN + 5-FU.
